Gleptoferron

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Gleptoferron
Accession Number
DB11417
Description

Colloid solution of ferric hydroxide, dextran & glucoheptonic acid.

Type
Small Molecule
Groups
Vet approved
Structure
Thumb
Weight
Average: 477.173
Monoisotopic: 477.054281
Chemical Formula
C13H25FeO15
Synonyms
  • Gleptoferronum

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Alendronic acidGleptoferron can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
AlmasilateAlmasilate can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy.
AluminiumAluminium can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium phosphateAluminium phosphate can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy.
AsenapineAsenapine can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium PhosphateGleptoferron can cause a decrease in the absorption of Calcium Phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium phosphate dihydrateGleptoferron can cause a decrease in the absorption of Calcium phosphate dihydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
CarbidopaGleptoferron can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

International/Other Brands
Gleptosil

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
898723IQHQ
CAS number
57680-55-4
InChI Key
QPUPHFVWBIOERP-MXIFXDQUSA-M
InChI
InChI=1S/C13H24O13.Fe.H2O2/c14-1-4-6(17)8(19)11(22)13(26-4)25-2-3(15)5(16)7(18)9(20)10(21)12(23)24;;1-2/h3-11,13-22H,1-2H2,(H,23,24);;1-2H/q;+1;/p-1/t3?,4-,5?,6-,7?,8+,9?,10?,11-,13+;;/m1../s1
IUPAC Name
lambda1-iron(1+) peroxol 2,3,4,5,6-pentahydroxy-7-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}heptanoate
SMILES
[Fe+].OO.[H]C(O)(CO[C@@]1([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]1([H])O)C([H])(O)C([H])(O)C([H])(O)C([H])(O)C([O-])=O

References

General References
  1. Pollmann DS, Smith JE, Stevenson JS, Schoneweis DA, Hines RH: Comparison of gleptoferron with iron dextran for anemia prevention in young pigs. J Anim Sci. 1983 Mar;56(3):640-4. [PubMed:6841298]
  2. Vermeer JE, Kuijpers AH, Elbers AR: [Comparison of the efficacy of two different iron supplements for anemia prevention in piglets]. Tijdschr Diergeneeskd. 2002 Feb 15;127(4):110-4. [PubMed:11885329]
  3. Guise HJ, Penny RH: Influence of supplementary iron in late pregnancy on the performance of sows and litters. Vet Rec. 1990 Oct 20;127(16):403-5. [PubMed:2267713]
  4. Loudenslager MJ, Ku PK, Whetter PA, Ullrey DE, Whitehair CK, Stowe HD, Miller ER: Importance of diet of dam and colostrum to the biological antioxidant status and parenteral iron tolerance of the pig. J Anim Sci. 1986 Dec;63(6):1905-14. [PubMed:3818467]
ChemSpider
34987780
RxNav
1855078

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility351.0 mg/mLALOGPS
logP-2.6ALOGPS
logP-5.8ChemAxon
logS-0.1ALOGPS
pKa (Strongest Acidic)3.23ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count13ChemAxon
Hydrogen Donor Count9ChemAxon
Polar Surface Area240.66 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity87.48 m3·mol-1ChemAxon
Polarizability34.54 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on February 25, 2016 11:36 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates